A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI.
Diabetes Obes MetabJul 30, 2026 (epub)
Eva Svehlikova, Christina Gatschelhofer, Bettina Lackner et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the pharmacokinetics and pharmacodynamics of a new concentrated insulin aspart formulation (AT278-U500) in 41 overweight and obese individuals with type 2 diabetes. AT278-U500 demonstrated significantly faster insulin absorption (t Early50%Cmax: 9 min) and a greater glucose-lowering effect within the first hour compared to standard insulin aspart and U500 human regular insulin.
Key findings
- AT278-U500 had a t Early50%Cmax of 9 min, compared to 35 min for InsAsp-U100 and 55 min for HumIns-U500.
- The glucose-lowering effect (AUC GIR,0-60min) was 2.02 times higher for AT278-U500 than InsAsp-U100.
- No inverse relationship between BMI and AUC GIR,0-60min was observed with AT278-U500.
Why it matters
The findings suggest that AT278-U500 could provide a more effective prandial insulin option for patients with type 2 diabetes, particularly those who are insulin-resistant and require high-dose therapy, regardless of their BMI.